bluebird bio (BLUE)
(Real Time Quote from BATS)
$0.91 USD
0.00 (0.08%)
Updated May 2, 2024 10:58 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 521 - 529 ( 529 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q1:14, Initial Results of LentiGlobin in Beta-Thal at Upcoming Scientific Meeting, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Beta-Thal Patient Enrolled in US Study of LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Beta-Thal Patient Enrolled in US Study of LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
2013 Year-End Results, Well-capitalized, with Programs on Track, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in Beta-thal Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in Beta-thal Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q3:13 EPS: Beginning Pivotal Studies; Well- Capitalized, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in CCALD Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at OUTPERFORM with a $40 Price Target: BLUE: Gene Therapy Is Back and BLUE
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D